Patents Examined by Jeanine Goldberg
-
Patent number: 6492111Abstract: A plurality of oligonucleotides are caused to bind specifically to target nucleic acid which is predictive of a disease state or a biological condition within cells containing the target nucleic acid. The respective oligonucleotides, which may be functionilized or may be present in the form of oligonucleotide analogs, carry with them a plurality of synthons. Such synthons, which may be identiphores, toxiphores, or other precursors to biologically effective molecules, interact when specific binding of the respective oligonucleotides occurs at sites adjacent to each other on the target nucleic acid. The resulting interaction gives rise to the synthesis, generation or release of highly active biological molecules in situ in the cell in which the specific binding takes place. This permits the use of extraordinarily toxic molecules for use in killing cells containing the target nucleic acids. Imaging and other uses are also provided by the present invention.Type: GrantFiled: November 25, 1998Date of Patent: December 10, 2002Assignee: Isis Pharmaceuticals, Inc.Inventor: David J. Ecker
-
Patent number: 6479236Abstract: Genetic polymorphisms are identified in the human UGT1 gene that alter UGT1-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT1 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.Type: GrantFiled: May 5, 1999Date of Patent: November 12, 2002Assignee: DNA Sciences Laboratories, Inc.Inventors: Laura Penny, Margaret Galvin
-
Patent number: 6476195Abstract: The present invention relates to novel human secreted protein (HNFGF20). Polypeptides of the invention are duseful in dianosis and treatment of disorders affecting the immune system.Type: GrantFiled: January 24, 2000Date of Patent: November 5, 2002Assignee: Human Genome Sciences, Inc.Inventors: George Komatsoulis, Craig A. Rosen, Steven M. Ruben, Roxanne D. Duan, Paul A. Moore, Yanggu Shi, David W. LaFleur, Ying-Fei Wei, Jian Ni, Kimberly A. Florence, Paul Young, Laurie A. Brewer, Daniel R. Soppet, Gregory A. Endress, Reinhard Ebner, Henrik Olsen, Michael Mucenski
-
Patent number: 6469150Abstract: The genes for bradykinin B1 receptor from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig have been cloned and characterized. In addition to the delineation of the nucleotide and amino acid sequences, methods for identifying modulators of bradykinin B1 receptor activity using these molecules is also described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided.Type: GrantFiled: May 22, 2000Date of Patent: October 22, 2002Assignee: Pharmacopeia, Inc.Inventors: Robert Horlick, Jiuqiao Zhao, Robert Swanson, Maria Webb, Barbara Strohl
-
Patent number: 6465185Abstract: A novel polymorphism in the human PC-1 gene is characterized, which is associated with an increased predisposition to developing insulin resistance. The polymorphism affects heterozygous and homozygous carriers of the allele. The subject nucleic acids and fragments thereof, encoded polypeptides, and antibodies specific for the polymorphic amino acid sequence are useful in determining a genetic predisposition to insulin resistance. The encoded protein is useful in drug screening for compositions that affect the activity of PC-1 and insulin receptor activity or expression.Type: GrantFiled: November 18, 1999Date of Patent: October 15, 2002Assignees: Instituto di Ricovero e Cura a Carattere Scientifico, The Regents of the University of CaliforniaInventors: Ira Goldfine, Vincenzo Trischitta, Riccardo Vigneri, Antonio Pizzuti, Lucia A. Frittitta
-
Patent number: 6455258Abstract: The present invention provides for methods of distinguishing melanocytic nevi, such as Spitz nevi, from malignant melanoma. The methods comprise contacting a nucleic acid sample from a patient with a probe which binds selectively to a target polynucleotide sequence on a chromosomal region such as 11p, which is usually amplified in Spitz nevi. The nucleic acid sample is typically from skin tumor cells located within a tumor lesion on the skin of the patient. Using another probe which binds selectively to a chromosomal region such as 1q, 6p, 7p, 9p, or 10q, which usually show altered copy number in melanoma, the method can determine that those tumor cells with no changes in copy number of 1q, 6p, 7p, 9p, or 10q, are not melanoma cells but rather Spitz nevus cells. The finding of amplifications of chromosome 11p would be an additional indication of Spitz nevus.Type: GrantFiled: April 13, 2001Date of Patent: September 24, 2002Assignee: The Regents of the University of CaliforniaInventors: Boris Bastian, Daniel Pinkel
-
Patent number: 6451524Abstract: The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of preselected disease states or biological conditions in cells containing the nucleic acid sequence. Members of a set of mRNA molecules from a common gene, but containing different sequences and structures, are compared. The gene is predictive of the disease state or biological condition in cells containing the gene. At least one molecular interaction site from among those present in the members of the set are identified. The molecular interaction site is present in cells likely to have the disease state or biological condition. At least one nucleic acid sequence from the molecular interaction site is ascertained.Type: GrantFiled: November 25, 1998Date of Patent: September 17, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventor: David J. Ecker
-
Patent number: 6441148Abstract: Xylanase DNA is recovered from soil by PCR amplification using degenerate primers. Because of the complexity of the soil samples, it is likely that the recovered product will include more than one species of polynucleotide. These recovered copies may be cloned into a host organism to produce additional copies of each individual species prior to characterization by sequencing. Recovered DNA which is found to vary from known xylanases can be used in several ways to facilitate production of novel xylanases for industrial application. First, the recovered DNA, or probes corresponding to portions thereof, can be used as a probe to screen DNA libraries and recover intact xylanase genes including the unique regions of the recovered DNA. Second, the recovered DNA or polynucleotides corresponding to portions thereof, can be inserted into a known xylanase gene to produce a recombinant xylanase gene with the sequence variations of the recovered DNA.Type: GrantFiled: August 6, 1998Date of Patent: August 27, 2002Assignee: Terragen Diversity, Inc.Inventors: Christopher C. A. Radomski, Kah Tong Seow, R. Antony J. Warren, Wai Ho Yap
-
Patent number: 6436645Abstract: An objective of this invention is to provide a method for predicting the risk of subject developing chronic pulmonary emphysema. To achieve the objective, this invention provides a method for predicting the risk of subject developing chronic pulmonary emphysema comprising determining the number of GT repeats within a GT repeat sequence located upstream of hemeoxygenase-1, in which if the number of the GT repeats is not less than 30, the subject has a high risk of developing chronic pulmonary emphysema.Type: GrantFiled: November 22, 2000Date of Patent: August 20, 2002Assignee: President of Tohoku UniversityInventors: Hidetada Sasaki, Shoji Okinaga, Mutsuo Yamaya, Katsutoshi Nakayama
-
Patent number: 6413720Abstract: Methods are provided for the isolation of newly synthesized mRNA. Such methods involve the incorporation of biotinylated rNTP analogues into cellular mRNA, and separating biotinylated mRNA from unlabeled RNA. The methods provided herein may be used, for example, for gene discovery, drug screens and studies of the regulation of gene expression.Type: GrantFiled: January 11, 1999Date of Patent: July 2, 2002Assignee: Signal Pharmaceuticals, Inc.Inventors: Jose R. Pardinas, Kyle W. H. Chan
-
Patent number: 6410724Abstract: The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.Type: GrantFiled: January 21, 2000Date of Patent: June 25, 2002Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Anne Dejean, Marie-Annick Buendia, Pascal Pineau, Hisaki Nagai, Pierre Tiollais
-
Patent number: 6383751Abstract: This invention relates to methods and nucleic acid probes for assessing characteristics of lipid metabolism in animals, and in particular to methods of predicting fat levels in meat, milk, or other fat depots of animals. Thus the invention provides a method of assessing the fat metabolism characteristics of an animal, comprising the step of testing the animal for the presence or absence of one or more markers selected from the group consisting of: a) an allele of the 5′ untranslated region of thyroglobulin; b) an allele of the DNA polymorphism CSSM34, associated with the gene encoding retinoic acid receptor gamma (RARG); and c) an allele of the DNA polymorphism ETH10, associated with 11-cis, 9-cis retinol dehydrogenase (RDH5). The invention is particularly applicable to predicting disposition of fat in muscle tissue, which produces the characteristic “marbling” of meat, and to assessment of milk fat content.Type: GrantFiled: July 18, 2000Date of Patent: May 7, 2002Inventor: William John Barendse
-
Patent number: 6372430Abstract: Nucleic acids for detecting Aspergillus species and other filamentous fungi are provided. Unique internal transcribed space 2 coding regions permit the development of nucleic acid probes specific for five different species of Aspergillus, three species of Fusarium, four species of Mucor, two species of Penecillium, five species of Rhizopus, one species of Rhizomucor, as well as probes for Absidia corymbifer, Cunninghamella elagans, Pseudallescheria boydii, and Sporothrix schenkii. Methods are disclosed for the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, absidia, Cunninghaemella, Pseudallescheria or Sporthrix in a subject. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an all-fungus nucleic acid probe.Type: GrantFiled: June 27, 2000Date of Patent: April 16, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Christine J. Morrison, Errol Reiss, Liliana Aidorevich, Jong Soo Choi
-
Patent number: 6329149Abstract: Teeth, the hardest substance in the human body, are frequently all that remain of a mortuary population from which direct human presence can be gleaned. As such their morphology is invaluable to physical anthropologists and investigators in allied disciplines. Methods currently used for purposes of extracting DNA from dental remains—e.g. bone-milling, crushing, and sectioning—result in total destruction of the teeth. This paper introduces the Reverse-Root-Canal, a protocol by which DNA of molecular weight higher than that obtainable through traditional destructive means, can be obtained from ancient dental remains without harm to the morphologically informative crown and roots.Type: GrantFiled: March 7, 2000Date of Patent: December 11, 2001Inventor: Janice Cori Cobb
-
Patent number: 6326148Abstract: The present invention provides methods of screening for colon carcinoma cells in a sample. The methods comprise providing a nucleic acid sample from a premalignant lesion in colorectal tissue from a human patient and contacting the sample with a nucleic acid probe that selectively hybridizes to a chromosomal region at 20q.Type: GrantFiled: July 12, 1999Date of Patent: December 4, 2001Assignee: The Regents of the University of CaliforniaInventors: Giovanni E. Pauletti, Dennis J. Slamon
-
Patent number: 6323335Abstract: The present invention provides mammalian retinoblastoma (Rb) protein-interacting zinc finger (RIZ) proteins, nucleic acid molecules encoding RIZ and antibodies specific for RIZ. The invention provides methods for identifying an agent that alters the association of a RIZ with a second molecule, which can bind to RIZ. The invention provides fragments of RIZ, PRD1-BF1, EVI-1, and egl-43. The invention provides methods for introducing a nucleic acid molecule encoding a RIZ into a cell and for contacting a cell with an effective agent in order to modulate a function of a cell. The invention further provides methods for detecting a RIZ in a sample by detecting RIZ or a nucleic acid molecule encoding RIZ.Type: GrantFiled: June 1, 2000Date of Patent: November 27, 2001Inventor: Shi Huang
-
Patent number: 6323331Abstract: This invention provides for an isolated nucleic acid which encodes a wildtype human Beclin and a mutant human Beclin. This invention also provides a vector containing the isolated nucleic acid which encodes a wildtype human Beclin. This invention also provides for a method of producing a wildtype human Beclin. This invention also provides for a purified, wildtype human Beclin. This invention also provides for a method for determining whether a subject has a predisposition for cancer. This invention also provides a method for determining whether a subject has cancer. This invention also provides for a method for inhibiting cell proliferation in cells unable to regulate themselves. This invention also provides for a method for treating a subject who has cancer. This invention also provides for a pharmaceutical composition composed of the and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition composed of the wildtype human Beclin.Type: GrantFiled: July 16, 1999Date of Patent: November 27, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventor: Beth C. Levine
-
Patent number: 6316195Abstract: Karnal bunt of wheat is caused by Tilletia indica Mitra. Recently, teliospores morphologically resembling T. indica were isolated from bunted ryegrass seeds and wheat seed washes. Previously developed PCR assays failed to differentiate T. indica from the newly discovered ryegrass pathogen, T. walkeri. The nucleotide sequence of a 2.3-kb region of mitochondrial DNA, previously amplified by PCR only from T. indica, was determined for three isolates of T. indica and for three isolates of T. walkeri. There was greater than 99% identity within either the T. indica group or the T. walkeri group of isolates, whereas there was approximately 3% divergence between isolates of these two Tilletia species. Five sets of PCR primers were made specific to T. indica, and three sets were designed specifically for T. walkeri based upon nucleotide differences within the mtDNA region.Type: GrantFiled: December 23, 1999Date of Patent: November 13, 2001Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Reid D. Frederick, Paul W. Tooley, Morris R. Bonde, David A. Knorr, Gary L. Peterson, Norman W. Schaad
-
Patent number: 6306596Abstract: Methods, employing a nucleotide integrase, for cleaving single-stranded RNA substrates, single-stranded DNA substrates, and double-stranded DNA substrates at specific sites and for inserting a nucleic acid molecule into the cleaved substrate are provided. One method uses a nucleotide integrase to cleave one strand of a double-stranded DNA substrate. The method comprises the steps of: providing an isolated nucleotide integrase comprising a group II intron RNA having two hybridizing sequences for hybridizing with two intron RNA binding sequences on the top strand of the DNA substrate, and a group II-intron encoded protein which binds to a first sequence element of the substrate; and reacting the nucleotide integrase with the double-stranded DNA substrate to permit the nucleotide integrase to cleave the top strand of the DNA substrate and to insert the group II intron RNA into the cleavage site.Type: GrantFiled: February 25, 1999Date of Patent: October 23, 2001Assignee: The Ohio State University Research FoundationInventors: Allen M. Lambowitz, Steven Zimmerly, Huatao Guo, Georg Mohr, Clifford James Beall
-
Patent number: RE37952Abstract: The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.Type: GrantFiled: August 15, 2000Date of Patent: December 31, 2002Assignee: Aventis Pharma S.A.Inventors: Fabien Schweighoffer, Bruno Tocque